HK Stock Market Move | GALAXIS TECH (02729) surged nearly 7% against the market trend, focusing on intelligent in-house logistics in the Siasun Robot & Automation sector. Revenue in September increased by over 60% compared to 25 years ago.
Cathay Land Technology (02729) rose nearly 7% against the market trend, and as of the time of writing, it increased by 4.4% to 31.32 Hong Kong dollars with a trading volume of 12.1688 million Hong Kong dollars.
GALAXIS TECH (02729) rose by nearly 7% against the market, rising by 4.4% as of the time of writing, to HK$31.32, with a trading volume of HK$121.688 million.
Public information shows that GALAXIS TECH focuses on the field of intelligent in-plant logistics with Siasun Robot&Automation, featuring three major product lines: multi-directional shuttle Siasun Robot&Automation, autonomous mobile Siasun Robot&Automation, and conveyor sorting Siasun Robot&Automation, deepening the intelligent upgrading of warehouse logistics in scenarios such as pharmaceuticals, e-commerce, and manufacturing. According to Frost & Sullivan data, based on revenue in 2024, GALAXIS TECH ranks among the top five comprehensive intelligent in-plant logistics Siasun Robot&Automation companies in China. In 2024, the company's VNA AMR shipment volume ranked first in China.
The prospectus shows that GALAXIS TECH achieved a revenue of 721 million yuan in 2024, a year-on-year increase of 30.8%; in the first nine months of 2025, it achieved a revenue of 552 million yuan, a year-on-year increase of 60.3%. As of the end of 2024, the company has implemented 1,530 projects, serving 779 customers, covering 28 segments including new energy, automotive, pharmaceuticals, e-commerce, and operating in 16 countries and regions globally.
Related Articles

China Securities Co., Ltd. reviews the A-share market in the first quarter of 2026: This bull market is more forward-looking in terms of regulation and will take timely measures to address overheated trading.

Jiangsu Aidea Pharmaceutical Group (688488.SH): A clinical trial for a new type 1 drug ACC085 injection in the field of HIV treatment will be conducted.

Subsidiary company of Shenzhen Nanshan Power (000037.SZ) plans to invest in the construction of a 300MW/600MWh independent energy storage power station in the Cuiheng New Area of Zhongshan City (Phases Two and Three) project.
China Securities Co., Ltd. reviews the A-share market in the first quarter of 2026: This bull market is more forward-looking in terms of regulation and will take timely measures to address overheated trading.

Jiangsu Aidea Pharmaceutical Group (688488.SH): A clinical trial for a new type 1 drug ACC085 injection in the field of HIV treatment will be conducted.

Subsidiary company of Shenzhen Nanshan Power (000037.SZ) plans to invest in the construction of a 300MW/600MWh independent energy storage power station in the Cuiheng New Area of Zhongshan City (Phases Two and Three) project.

RECOMMEND

Hong Kong Stocks Surge! Buying Opportunity Or Wait And See? Analysts Provide Comprehensive Interpretation
02/04/2026

Narrative Drives Everything As China’s AI Newcomers Enter An Era Of Extreme Volatility, Retail Investors Flood In
02/04/2026

Fund Cohort Stocks Rally As Institutional Confidence In Hong Kong Equities Shows Signs Of Repair
02/04/2026


